Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.

Erkan TopkanAli Ayberk BesenYurday OzdemirAhmet KucukHuseyin MertsoyluBerrin PehlivanUgur Selek

Published in: Mediators of inflammation (2020)

The outcomes displayed here qualified the pretreatment SII as a novel independent prognostic index for predicting survival outcomes of newly diagnosed GBM patients undergoing postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide.

Keyphrases

newly diagnosed
patients undergoing
early stage
locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
oxidative stress
radiation induced
adipose tissue
insulin resistance
weight loss
drug induced